In a retrospective study of 1099 patients with laboratory-confirmed COVID-19 in China, Guan et al2 reported presenting symptoms. The cohort included patients in both the hospital and outpatient setting. There were no reported definitive neurological signs or symptoms on presentation. Additionally, seizures and epilepsy were not listed among coexisting disorders before COVID-19 infection. The reported presenting symptoms of headache (13.6%), fatigue (38.1%), and myalgia or arthralgia (14.9%), theoretically neurologically related, are more typically related to systemic effects of the associated viral infection. Additionally, there were no reported neurological signs. Two subsequently published hospital-based studies reporting initial clinical features COVID-19 showed similar findings, with no definitive presenting neurological signs or symptoms.4,5 Focusing on the pediatric population, Dong et al6 reported a retrospective nationwide Chinese epidemiological case series of 2135 patients <18 years old with COVID-19. Only 6% of children in the study developed severe or critical disease, in contrast to other comparably designed studies in adult patients showing more severe COVID-19 complications. However, infants (less than 1 year old) and young children (1-5 years old) were at higher risk of a worse clinical course than older pediatric patients. There was no reported incidence of seizures.